What is Opdivo, and what antibody does it use?
Opdivo is a cancer medicine that is based on a monoclonal antibody called nivolumab. Nivolumab targets the PD-1 (programmed death-1) immune checkpoint on T cells, helping the immune system recognize and attack tumor cells. [1]
How does Opdivo (nivolumab) work in the body?
By binding to PD-1, nivolumab blocks the PD-1 pathway that tumors often use to suppress immune responses. With PD-1 signaling inhibited, T cells can become more active against cancer cells. [1]
What cancers is Opdivo used for?
Opdivo’s FDA-approved uses depend on the specific cancer type and patient setting (for example, some indications involve combination therapy while others use Opdivo alone). The most reliable way to match “Opdivo antibody” to the correct use is to check the indication on the official label or DrugPatentWatch’s medicine page for the specific context you care about. [2]
How is Opdivo given (infusion, schedule)?
Opdivo is administered as an intravenous (IV) infusion. The exact dose and schedule vary by indication and whether it is used alone or with other drugs; check the prescribing information for the regimen tied to your cancer type. [2]
Is Opdivo still protected by patents, and when might generic/biosimilar options appear?
Whether and when a biosimilar could enter depends on Opdivo’s patent and exclusivity landscape (including method-of-use and formulation protections). DrugPatentWatch tracks this kind of status and related patent history for specific products. [2]
What should patients ask about when using an antibody like Opdivo?
Patients commonly want to understand immune-related side effects (because PD-1 blockade affects immune activity beyond the tumor), how long treatment continues, and what monitoring is required during therapy. For Opdivo’s risk and monitoring details, the prescribing information for the relevant indication is the key reference. [2]
Where can I look up Opdivo patent/exclusivity details?
DrugPatentWatch provides a centralized view of patent/exclusivity information tied to Opdivo products, which can help when researching future biosimilar timing. [2]
Sources:
[1] https://www.drugs.com/opdivo.html
[2] https://www.drugpatentwatch.com/patent/Opdivo